124358-24-3

Usage

InChI:InChI=1/C10H11NO4/c1-3-15-10(12)9-6-8(11(13)14)5-4-7(9)2/h4-6H,3H2,1-2H3

Upstream product

• 64-17-5 ethanol 
• 1975-52-6 5-nitro-o-toluic acid 

Downstream Products

• 7335-32-2 ethyl 5-amino-2-methylbenzoate 
• 34265-55-9 ethyl 3-hydroxy-6-methylbenzoate 
• 126210-14-8 Astrogorgadiol 
• 210987-65-8 [5-(2-Methoxy-ethoxymethoxy)-2-methyl-phenyl]-methanol 
• 210987-70-5 2-Chloromethyl-4-(2-methoxy-ethoxymethoxy)-1-methyl-benzene 
• 210987-74-9 2-Iodomethyl-4-(2-methoxy-ethoxymethoxy)-1-methyl-benzene 
• 210987-59-0 5-(2-Methoxy-ethoxymethoxy)-2-methyl-benzoic acid ethyl ester 
• 169217-42-9 Calicoferol E 
• 210987-78-3 (1R,3aS,4S,7aR)-1-((R)-1,5-Dimethyl-hexyl)-4-{2-[5-(2-methoxy-ethoxymethoxy)-2-methyl-phenyl]-ethyl}-7a-methyl-octahydro-inden-5-one 
• 60390-42-3 ethyl 5-amino-2-methylnicotinate 
• 896160-38-6 5-(3-(2-cyanopropan-2-yl)benzamido)-2-methylbenzoic acid 
• 1351238-76-0 ethyl 5-(3-(2-cyanopropan-2-yl)benzamido)-2-methylbenzoate 
• 1351237-97-2 5-(3-(2-cyanopropan-2-yl)benzamido)-2-methyl-N-(thieno[2,3-b]pyrazin-6-yl)benzamide 
• 1606169-48-5 diethyl (2-methyl-5-nitrobenzyl)phosphonate 

Relevant academic research and scientific papers

Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors

Although there is a significant effort in the design of a selective CDK9/CycT1 inhibitor, no compound has been proven to be a specific inhibitor of this kinase so far. The aim of this research was to develop novel and selective phosphorus containing CDK9/CycT1 inhibitors. Molecules bearing phosphonamidate, phosphonate, and phosphinate moieties were synthesized. Prepared compounds were evaluated in an enzymatic CDK9/CycT1 assay. The most potent molecules were tested in cell-based toxicity and HIV proliferation assays. Selectivity of shortlisted compounds against CDKs and other kinases was tested. The best compound was shown to be a highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity.

THIENO (2, 3B) PYRAZINE COMPOUNDS AS B-RAF INHIBITORS

The invention relates to compounds according to general Formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of cancer.

THIENO (2, 3B) PYRAZINE COMPOUNDS AS B - RAF INHIBITORS

The invention relates to compounds according to general Formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of cancer.

Synthesis of symmetric diester-functionalised Troeger's base analogues

The yields of ester-functionalised Troeger's base analogues are dramatically improved by incorporating an electron-donating group on the aromatic ring and/or enhancing solubil- ity of the aniline unit. In addition to 2,8-diester compounds, 1,7-, 3,9- and 4,10-diester-functionalised Troeger's base analogues have been prepared for the first time.

ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES

Disclosed is a compound of Formula (I) in which W and R1-R6 are defined herein. Also disclosed is a method of treating spinal muscular atrophy, as well as methods of using such compounds to increase SMN expression, increase EAAT2 expression, or increase the expression of a nucleic acid that encodes a translational stop codon introduced directly or indirectly by mutation or frameshift.

COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES

Compounds of Formula (I) or (II) useful for the treatment of spinal muscular atrophy or other uses, as well as methods of using such compounds to increase SMN expression, increase EAAT2 expression, or increase the expression of a nucleic acid that encodes

Synthesis of calicoferol E and astrogorgiadiol, two marine 9,10- secosteroids

The synthesis of two marine 9,10-secosteroids, calicoferol E and astrogorgiadiol, has been achieved starting from vitamin D3. The conceived approach establishes a general convergent Strategy toward the synthesis of 9,10-secosteroids.